<H1>Chapter DOI: 10.1208/aapsj070240<br/>Cited-By Count: 17</H1><table border="1" width="30%"><tr><td>Total References</td><td>101</td></tr><tr><td>Springer references</td><td>7</td></tr><tr><td>Non Springer references</td><td>94</td></tr><tr><td>BibStructured Count</td><td width="10%">101</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>62</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>20</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>1</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>21</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>21</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>12</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Vrijens B, Tousset E, Gaillard P, Metry J, Urquhart J. Major features of dose omissions in 87 ambulatory drug trials.<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 2005;77:P99.</td><td><a href=http://dx.doi.org/10.1016/j.clpt.2005.01.006>10.1016/j.clpt.2005.01.006</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Author_FamilyName_1, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance.<Emphasis Type="Italic">Am J Hosp Pharm.</Emphasis> 1991;48:1978&#8211;1988.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3</td><td>BibBook</td><td>Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press Ltd; 1991.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1097/00013414-199101030-00005>10.1097/00013414-199101030-00005</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle, Year</td><td>CrossRef</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Didlake RH, Dreyfus K, Kermanet RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants.<Emphasis Type="Italic">Transplant Proc.</Emphasis> 1988;20(suppl 3):63&#8211;69.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Kastrissios H, Blaschke TF. Therapeutic implications of nonadherence with antiretroviral drug regimens.<Emphasis Type="Italic">HIV</Emphasis>. 1998;8:24&#8211;28.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens.<Emphasis Type="Italic">Postgrad Med J.</Emphasis> 1992;68(suppl 3):S49-S59.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy.<Emphasis Type="Italic">Clin Pharmacokinet.</Emphasis> 1997;32:345&#8211;356.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Hong JH, Sumrani N, Delaney V, et al. Causes of late renal allograft failure in the ciclosporin era.<Emphasis Type="Italic">Nephron.</Emphasis> 1992;62:272&#8211;279.</td><td><a href=http://dx.doi.org/10.1159/000187058>10.1159/000187058</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Author_FamilyName_1, Author_FamilyName_2, FirstPage, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Dunn J, Golden D, Van Buren CT, et al. Causes of graft loss beyond two years in the cyclosporine era.<Emphasis Type="Italic">Transplantation</Emphasis>. 1990;49:349&#8211;353.</td><td><a href=http://dx.doi.org/10.1097/00007890-199002000-00024>10.1097/00007890-199002000-00024</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_1, Author_FamilyName_2, FirstPage, JournalTitle, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research.<Emphasis Type="Italic">Clin Pharmacokinet.</Emphasis> 1994;27:202&#8211;215.</td><td><a href=http://dx.doi.org/10.2165/00003088-199427030-00004>10.2165/00003088-199427030-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care.<Emphasis Type="Italic">J Clin Epidemiol.</Emphasis> 1997;50:385&#8211;391.</td><td><a href=http://dx.doi.org/10.1016/S0895-4356(97)00041-3>10.1016/S0895-4356(97)00041-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique.<Emphasis Type="Italic">JAMA</Emphasis>. 1989;261:3273&#8211;3277.</td><td><a href=http://dx.doi.org/10.1001/jama.261.22.3273>10.1001/jama.261.22.3273</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.<Emphasis Type="Italic">Pharmacoeconomics</Emphasis>. 1999;15:423&#8211;434.</td><td><a href=http://dx.doi.org/10.2165/00019053-199915050-00001>10.2165/00019053-199915050-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.<Emphasis Type="Italic">N Engl J Med.</Emphasis> 1994;330:1179&#8211;1184.</td><td><a href=http://dx.doi.org/10.1056/NEJM199404283301702>10.1056/NEJM199404283301702</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice.<Emphasis Type="Italic">Clin Ther.</Emphasis> 1999;21:1074&#8211;1090.</td><td><a href=http://dx.doi.org/10.1016/S0149-2918(99)80026-5>10.1016/S0149-2918(99)80026-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee &amp; Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).<Emphasis Type="Italic">AIDS Care.</Emphasis> 2000;12: 255&#8211;266.</td><td><a href=http://dx.doi.org/10.1080/09540120050042891>10.1080/09540120050042891</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>de Klerk E, van der Linden SJ. Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device.<Emphasis Type="Italic">Br J Rheumatol.</Emphasis> 1996;35:60&#8211;65.</td><td><a href=http://dx.doi.org/10.1093/rheumatology/35.1.60>10.1093/rheumatology/35.1.60</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Lee JY, Kusek JW, Greene PF, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.<Emphasis Type="Italic">Am J Hypertens.</Emphasis> 1996;9:719&#8211;725.</td><td><a href=http://dx.doi.org/10.1016/0895-7061(96)00056-8>10.1016/0895-7061(96)00056-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Bloch M, Gur E, Shalev AY. Hypouricemic effect of zuclopenthixol: a potential marker of drug compliance?<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 1992;109:377&#8211;378.</td><td><a href=http://dx.doi.org/10.1007/BF02245887>10.1007/BF02245887</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Kapur S, Ganguli R, Ulrich R, et al. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics.<Emphasis Type="Italic">Schizophr Res.</Emphasis> 1991;6:49&#8211;53.</td><td><a href=http://dx.doi.org/10.1016/0920-9964(91)90020-R>10.1016/0920-9964(91)90020-R</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Hardy E, Kumar S, Peaker S, et al. A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release &#8216;therapeutic drug&#8217; (metoprolol, Metoros) in reflecting incomplete compliance by volunteers.<Emphasis Type="Italic">Br J Clin Pharmacol.</Emphasis> 1990;30:437&#8211;441.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Maenpaa H, Javela K, Pikkarainen JH, et al. Minimal doses of digoxin: a new marker for compliance to medication.<Emphasis Type="Italic">Eur Heart J.</Emphasis> 1987;8(suppl 1):31&#8211;37.</td><td><a href=http://dx.doi.org/10.1093/eurheartj/8.suppl_I.31>10.1093/eurheartj/8.suppl_I.31</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, ArticleTitle, Year, Author_FamilyName_1, FirstPage, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Pekovic V, Mayanja H, Vjecha M, et al. Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration.<Emphasis Type="Italic">J Clin Epidemiol.</Emphasis> 1998;51:597&#8211;607.</td><td><a href=http://dx.doi.org/10.1016/S0895-4356(98)00033-X>10.1016/S0895-4356(98)00033-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Lu J, Gries JM, Verotta D, et al. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn.</Emphasis> 2001;28:343&#8211;362.</td><td><a href=http://dx.doi.org/10.1023/A:1011582713692>10.1023/A:1011582713692</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Melbourne KM, Geletko SM, Brown SL, et al. Medication adherence in patients with HIV infection: a comparison of two measurement methods.<Emphasis Type="Italic">AIDS Read.</Emphasis> 1999;9:329&#8211;338.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26</td><td>BibBook</td><td>Carroll RJ, Ruppert D, Stefanski LA. Measurement error in nonlinear models. Boca Raton, FL: CRC Press, 1998.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-1-4899-4477-1>10.1007/978-1-4899-4477-1</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1, BookTitle</td><td>CrossRef</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Kenna LA, Sheiner LB. Estimating treatment effect in the presence of non-compliance measured with error: precision and robustness of data analysis methods.<Emphasis Type="Italic">Stat Med.</Emphasis> 2004;23:3561&#8211;3580.</td><td><a href=http://dx.doi.org/10.1002/sim.1830>10.1002/sim.1830</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibBook</td><td>Kenna LA. Estimating treatment effect in the presence of non-compliance measured with error: power, precision and robustness of data analysis methods [dissertation].<Emphasis Type="Italic">PhD Thesis</Emphasis>. San Francisco, CA; University of California San Francisco: 2001.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/sim.1830>10.1002/sim.1830</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Catania JA, Binson D, Canchola J, et al. Effects of interviewer gender, interviewer choice, and item wording on response to questions concerning sexual behavior.<Emphasis Type="Italic">Public Opinion Quarterly.</Emphasis> 1996;60:345&#8211;375.</td><td><a href=http://dx.doi.org/10.1086/297758>10.1086/297758</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Kaplan RM, Simon HJ. Compliance in medical care: reconsideration of self-predictions.<Emphasis Type="Italic">Ann Behav Med.</Emphasis> 1990;12:66&#8211;71.</td><td><a href=http://dx.doi.org/10.1207/s15324796abm1202_2>10.1207/s15324796abm1202_2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Hyland ME, Kenyon CA, Allen R, et al. Diary keeping in asthma: comparison of written and electronic methods.<Emphasis Type="Italic">BMJ</Emphasis>. 1993;306:487&#8211;489.</td><td><a href=http://dx.doi.org/10.1136/bmj.306.6876.487>10.1136/bmj.306.6876.487</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Year, Author_FamilyName_2, FirstPage, JournalTitle, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.<Emphasis Type="Italic">AIDS</Emphasis>. 2000;14:357&#8211;366.</td><td><a href=http://dx.doi.org/10.1097/00002030-200003100-00008>10.1097/00002030-200003100-00008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Feinstein AR. On white-coat effects and the electronic monitoring of compliance.<Emphasis Type="Italic">Arch Intern Med.</Emphasis> 1990;150:1377&#8211;1378.</td><td><a href=http://dx.doi.org/10.1001/archinte.150.7.1377>10.1001/archinte.150.7.1377</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors.<Emphasis Type="Italic">Ann Intern Med.</Emphasis> 2001;134:968&#8211;977.</td><td><a href=http://dx.doi.org/10.7326/0003-4819-134-10-200105150-00011>10.7326/0003-4819-134-10-200105150-00011</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, Author_FamilyName_1, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments.<Emphasis Type="Italic">Control Clin Trials.</Emphasis> 1997;18:187&#8211;203.</td><td><a href=http://dx.doi.org/10.1016/S0197-2456(96)00235-8>10.1016/S0197-2456(96)00235-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Robins JM. Correction for non-compliance in equivalence trials.<Emphasis Type="Italic">Stat Med.</Emphasis> 1998;17:269&#8211;302; discussion 387&#8211;389.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0258(19980215)17:3&lt;269::AID-SIM763&gt;3.0.CO;2-J>10.1002/(SICI)1097-0258(19980215)17:3&lt;269::AID-SIM763&gt;3.0.CO;2-J</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Goetghebeur E, Molenberghs G, Katz J. Estimating the causal effect of compliance on binary outcome in randomized controlled trials.<Emphasis Type="Italic">Stat Med.</Emphasis> 1998;17:341&#8211;355.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0258(19980215)17:3&lt;341::AID-SIM766&gt;3.0.CO;2-X>10.1002/(SICI)1097-0258(19980215)17:3&lt;341::AID-SIM766&gt;3.0.CO;2-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Efron B, Feldman D. Compliance as an explanatory variable in clinical trials.<Emphasis Type="Italic">J Am Stat Assoc.</Emphasis> 1991;86:9&#8211;22.</td><td><a href=http://dx.doi.org/10.2307/2289707>10.2307/2289707</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials.<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 1995;57:6&#8211;15.</td><td><a href=http://dx.doi.org/10.1016/0009-9236(95)90260-0>10.1016/0009-9236(95)90260-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Angrist JD, Imbens GW, Rubin DR. Identification of causal effects using instrumental variables.<Emphasis Type="Italic">J Am Stat Assoc.</Emphasis> 1996;91:444&#8211;472.</td><td><a href=http://dx.doi.org/10.2307/2291629>10.2307/2291629</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Albert JM, Demets DL. On a model-based approach to estimating efficacy in clinical trials.<Emphasis Type="Italic">Stat Med.</Emphasis> 1994;13:2323&#8211;2335.</td><td><a href=http://dx.doi.org/10.1002/sim.4780132204>10.1002/sim.4780132204</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Jonsson EN, Wade JR, Almqvist G, et al. Discrimination between rival dosing histories.<Emphasis Type="Italic">Pharm Res.</Emphasis> 1997;14:984&#8211;991.</td><td><a href=http://dx.doi.org/10.1023/A:1012184808192>10.1023/A:1012184808192</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Cheng CW, Woo KS, Chan JC, et al. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease.<Emphasis Type="Italic">Br J Clin Pharmacol.</Emphasis> 2004;58:528&#8211;535.</td><td><a href=http://dx.doi.org/10.1111/j.1365-2125.2004.02202.x>10.1111/j.1365-2125.2004.02202.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice.<Emphasis Type="Italic">Am J Med.</Emphasis> 2002;113:625&#8211;629.</td><td><a href=http://dx.doi.org/10.1016/S0002-9343(02)01303-7>10.1016/S0002-9343(02)01303-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs.<Emphasis Type="Italic">Med J Aust.</Emphasis> 1996;164:208&#8211;211.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care.<Emphasis Type="Italic">Am J Manag Care.</Emphasis> 1999;5:437&#8211;444.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR47</td><td>BibArticle</td><td>Larsen J, Andersen M, Kragstrup J, et al. High persistence of statin use in a Danish population: compliance study 1993&#8211;1998.<Emphasis Type="Italic">Br J Clin Pharmacol.</Emphasis> 2002;53:375&#8211;378.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2125.2002.01563.x>10.1046/j.1365-2125.2002.01563.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Hughes DA, Walley T. Predicting &#8220;real world&#8221; effectiveness by integrating adherence with pharmacodynamic modeling.<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 2003;74:1&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(03)00091-2>10.1016/S0009-9236(03)00091-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Williams-Deane M, Potter LS. Current oral contraceptive use instructions: An analysis of patient package inserts.<Emphasis Type="Italic">Fam Plann Perspect.</Emphasis> 1992;24:111&#8211;115.</td><td><a href=http://dx.doi.org/10.2307/2135540>10.2307/2135540</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50</td><td>BibArticle</td><td>Urquhar J. Erratic patient compliance with prescribed drug regiments: target for drug delivery systems.<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 2000;67:331&#8211;334.</td><td><a href=http://dx.doi.org/10.1067/mcp.2000.105582>10.1067/mcp.2000.105582</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51</td><td>BibArticle</td><td>Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness.<Emphasis Type="Italic">Heart.</Emphasis> 2002;88:203&#8211;206.</td><td><a href=http://dx.doi.org/10.1136/heart.88.2.203>10.1136/heart.88.2.203</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52</td><td>BibArticle</td><td>Johnson BF, Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs.<Emphasis Type="Italic">Am J Ther.</Emphasis> 1994;1:260&#8211;267.</td><td><a href=http://dx.doi.org/10.1097/00045391-199412000-00003>10.1097/00045391-199412000-00003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53</td><td>BibArticle</td><td>Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol.<Emphasis Type="Italic">Br J Clin Pharmacol.</Emphasis> 1982;13(suppl 2):345S-351S.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/0002-8703(82)90142-9>10.1016/0002-8703(82)90142-9</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_1, IssueID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR54</td><td>BibArticle</td><td>Vaur L, Dutrey-Dupagne C, Boussac J, et al. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients.<Emphasis Type="Italic">J Cardiovasc Pharmacol.</Emphasis> 1995;26:127&#8211;131.</td><td><a href=http://dx.doi.org/10.1097/00005344-199507000-00020>10.1097/00005344-199507000-00020</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55</td><td>BibArticle</td><td>Leenen FH, Fourney A, Notman G, et al. Persistence of antihypertensive effect after &#8216;missed doses&#8217; of calcium antagonist with long (amlodipine) vs short (diltiazem), elimination half-life.<Emphasis Type="Italic">Br J Clin Pharmacol.</Emphasis> 1996;41:83&#8211;88.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR56</td><td>BibArticle</td><td>Mallion JM, Meilhac B, Tremel F, et al. Use of a microprocessor-equipped tablet box in monitoring compliance with antihypertensive treatment.<Emphasis Type="Italic">J Cardiovasc Pharmacol</Emphasis>. 1992;19(suppl 2):S41-S48.</td><td><a href=http://dx.doi.org/10.1097/00005344-199219002-00011>10.1097/00005344-199219002-00011</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Year, Author_FamilyName_1, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR57</td><td>BibArticle</td><td>Lee SY, Song XY. Bayesian analysis of structural equation models with dichotomous variables.<Emphasis Type="Italic">Stat Med.</Emphasis> 2003;22:3073&#8211;3088.</td><td><a href=http://dx.doi.org/10.1002/sim.1544>10.1002/sim.1544</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58</td><td>BibArticle</td><td>Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance.<Emphasis Type="Italic">JAMA</Emphasis>. 1998;279:1997&#8211;1983.</td><td><a href=http://dx.doi.org/10.1001/jama.279.24.1977>10.1001/jama.279.24.1977</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59</td><td>BibArticle</td><td>Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy.<Emphasis Type="Italic">JAMA</Emphasis>. 1996;276:1955&#8211;1956.</td><td><a href=http://dx.doi.org/10.1001/jama.276.24.1955>10.1001/jama.276.24.1955</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60</td><td>BibArticle</td><td>Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel.<Emphasis Type="Italic">JAMA</Emphasis>. 1998;279:1984&#8211;1991.</td><td><a href=http://dx.doi.org/10.1001/jama.279.24.1984>10.1001/jama.279.24.1984</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61</td><td>BibArticle</td><td>Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations.<Emphasis Type="Italic">AIDS</Emphasis>. 2003;17:1925&#8211;1932.</td><td><a href=http://dx.doi.org/10.1097/00002030-200309050-00011>10.1097/00002030-200309050-00011</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62</td><td>BibArticle</td><td>Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.<Emphasis Type="Italic">Antimicrob Agents Chemother.</Emphasis> 2003;47:130&#8211;137.</td><td><a href=http://dx.doi.org/10.1128/AAC.47.1.130-137.2003>10.1128/AAC.47.1.130-137.2003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63</td><td>BibChapter</td><td>Urquhart J. Non-compliance: the ultimate absorption barrier. In: Prescott LF, Nimmo WS, eds. Novel Drug Delivery and Its Therapeutic Applications, Chichester, UK: John Wiley &amp; Sons, 1989;127&#8211;137.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR64</td><td>BibArticle</td><td>Kastrissios H, Suarez JR, Katzenstein D, et al. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial.<Emphasis Type="Italic">AIDS</Emphasis>. 1998;12:2295&#8211;2303.</td><td><a href=http://dx.doi.org/10.1097/00002030-199817000-00011>10.1097/00002030-199817000-00011</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65</td><td>BibArticle</td><td>Girard P, Sheiner LB, Kastrissios H, et al. Do we need full compliance data for population pharmacokinetic analysis?<Emphasis Type="Italic">J Pharmacokinet Biopharm.</Emphasis> 1996;24:265&#8211;282.</td><td><a href=http://dx.doi.org/10.1007/BF02353671>10.1007/BF02353671</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66</td><td>BibArticle</td><td>Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance.<Emphasis Type="Italic">Stat Med.</Emphasis> 1998;17:2313&#8211;2333.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0258(19981030)17:20&lt;2313::AID-SIM935&gt;3.0.CO;2-V>10.1002/(SICI)1097-0258(19981030)17:20&lt;2313::AID-SIM935&gt;3.0.CO;2-V</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67</td><td>BibBook</td><td>Vrijens B. Analyzing time-varying patterns of human exposure to xenobiotics and their biomedical impact. Ghent, Belgium: University of Ghent; 2002.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR68</td><td>BibArticle</td><td>Labb&#233; L, Hammer SM, Mellors JW, et al. A Markov model for the effect of covariates including drug adherence on longitudinal viral response in HIV patients.<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 2004;75:P90.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/j.clpt.2003.11.343>10.1016/j.clpt.2003.11.343</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR69</td><td>BibArticle</td><td>Labb&#233; L, Verotta D. A non-linear mixed effect dynamic model using adherence to treatment to describe long-term therapy outcome in HIV-patients.<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 2005;77:P90.</td><td><a href=http://dx.doi.org/10.1016/j.clpt.2004.09.007>10.1016/j.clpt.2004.09.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70</td><td>BibArticle</td><td>Diggle P, Kenward MG. Informative drop-out in longitudinal data analysis.<Emphasis Type="Italic">Appl Stats.</Emphasis> 1994;43:49&#8211;93.</td><td><a href=http://dx.doi.org/10.2307/2986113>10.2307/2986113</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71</td><td>BibArticle</td><td>Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn.</Emphasis> 2003;30:83&#8211;103.</td><td><a href=http://dx.doi.org/10.1023/A:1023249510224>10.1023/A:1023249510224</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72</td><td>BibArticle</td><td>Noordmohamed SE, Henry WK, Rhame FS, et al. Strategies for control of zidovudine concentrations in serum.<Emphasis Type="Italic">Antimicrob Agents Chemother</Emphasis>. 1995;39:2792&#8211;2797.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR73</td><td>BibArticle</td><td>Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.<Emphasis Type="Italic">Am J Med.</Emphasis> 2003;115:632&#8211;641.</td><td><a href=http://dx.doi.org/10.1016/j.amjmed.2003.07.007>10.1016/j.amjmed.2003.07.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74</td><td>BibArticle</td><td>Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.<Emphasis Type="Italic">Ann Intern Med.</Emphasis> 1999;131:81&#8211;87.</td><td><a href=http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00002>10.7326/0003-4819-131-2-199907200-00002</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, Year, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR75</td><td>BibArticle</td><td>Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in &#8220;revolving door&#8221; schizophrenic patients.<Emphasis Type="Italic">J Clin Psychiatry</Emphasis>. 1996;57:337&#8211;345.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR76</td><td>BibArticle</td><td>Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits.<Emphasis Type="Italic">Arch Intern Med.</Emphasis> 1990;150:1509&#8211;1510.</td><td><a href=http://dx.doi.org/10.1001/archinte.150.7.1509>10.1001/archinte.150.7.1509</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77</td><td>BibArticle</td><td>Waeber B, Leonetti G, Kolloch R, et al. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study.<Emphasis Type="Italic">J Hypertens.</Emphasis> 1999;17:1041&#8211;1045.</td><td><a href=http://dx.doi.org/10.1097/00004872-199917070-00022>10.1097/00004872-199917070-00022</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78</td><td>BibArticle</td><td>Kastrissios H, Blaschke TF. Medication compliance as a feature in drug development.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol.</Emphasis> 1997;37:451&#8211;475.</td><td><a href=http://dx.doi.org/10.1146/annurev.pharmtox.37.1.451>10.1146/annurev.pharmtox.37.1.451</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR79</td><td>BibArticle</td><td>Kass MA, Meltzer DW, Gordon M, et al. Compliance with topical pilocarpine treatment.<Emphasis Type="Italic">Am J Ophthalmol.</Emphasis> 1986;101:515&#8211;523.</td><td><a href=http://dx.doi.org/10.1016/0002-9394(86)90939-6>10.1016/0002-9394(86)90939-6</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, Author_FamilyName_1, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR80</td><td>BibChapter</td><td>Peck CC. Non-compliance and clinical trials: regulatory perspectives. In: Metry JM, Meyer UA, eds. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Chichester, UK: John Wiley &amp; Sons, 1999;97&#8211;102.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/047084633X>10.1002/047084633X</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, ChapterTitle</td><td>CrossRef</td></tr><tr><td>CR81</td><td>BibChapter</td><td>Hasford J. Design and analysis of clinical trials of compliance, In: Metry JM, Meyer UA, eds. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Chichester, UK: John Wiley &amp; Sons, 1999;23&#8211;40.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/047084633X>10.1002/047084633X</a></td><td><b>CrossRef-Meta</b></td>
<td>ChapterTitle, Year</td><td>CrossRef</td></tr><tr><td>CR82</td><td>BibArticle</td><td>Haynes RB, Montague P, Oliver T, et al. Interventions for helping patients to follow prescriptions for medications.<Emphasis Type="Italic">Cochrane Database Syst Rev.</Emphasis> 2000;2:CD000011.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/14651858.CD000011>10.1002/14651858.CD000011</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR83</td><td>BibArticle</td><td>Volmink J, Garner P. Directly observed therapy for treating tuberculosis.<Emphasis Type="Italic">Cochrane Database Syst Rev.</Emphasis> 2001;4:CD003343.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/14651858.CD003343.pub3>10.1002/14651858.CD003343.pub3</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR84</td><td>BibArticle</td><td>Barker J, Millard J. Directly observed therapy and treatment adherence.<Emphasis Type="Italic">Lancet</Emphasis>. 2000;356:1030&#8211;1; author reply 1032.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(05)72650-7>10.1016/S0140-6736(05)72650-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR85</td><td>BibArticle</td><td>Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals.<Emphasis Type="Italic">Drug Info J.</Emphasis> 1998;22:363&#8211;378.</td><td><a href=http://dx.doi.org/10.1177/009286158802200310>10.1177/009286158802200310</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR86</td><td>BibArticle</td><td>Sheiner LB. Learning versus confirming in clinical drug development.<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 1997;61:275&#8211;291.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(97)90160-0>10.1016/S0009-9236(97)90160-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87</td><td>BibArticle</td><td>Girard P. Clinical trial simulation: a tool for understanding study failures and preventing them.<Emphasis Type="Italic">Basic Clin Pharmacol Toxicol.</Emphasis> 2005;96:228&#8211;234.</td><td><a href=http://dx.doi.org/10.1111/j.1742-7843.2005.pto960313.x>10.1111/j.1742-7843.2005.pto960313.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR88</td><td>BibChapter</td><td>Lasagn L, Hutt PB. Health care, research, and regulatory impact of noncompliance. In: Cramer JA, Spilker B, eds. Compliance in Medical Practice and Clinical Trials, JA. New York: Raven Press, 1991;393&#8211;403.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR89</td><td>BibArticle</td><td>Morris SE, Groom GV, Cameron ED, et al. Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill (&#8216;Microgynon 30&#8217;) omission.<Emphasis Type="Italic">Contraception</Emphasis>. 1979;20:61&#8211;69.</td><td><a href=http://dx.doi.org/10.1016/0010-7824(79)90045-3>10.1016/0010-7824(79)90045-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR90</td><td>BibArticle</td><td>Chowdhury V, Joshi UM, Gopalkrishna K, et al. &#8216;Escape&#8217; ovulation in women due to the missing of low dose combination oral contraceptive pills.<Emphasis Type="Italic">Contraception</Emphasis>. 1980;22:241&#8211;247.</td><td><a href=http://dx.doi.org/10.1016/S0010-7824(80)80003-5>10.1016/S0010-7824(80)80003-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR91</td><td>BibArticle</td><td>Wang E, Shi S, Cekan SZ, et al. Hormonal consequences of &#8220;missing the pill&#8221;.<Emphasis Type="Italic">Contraception</Emphasis>. 1982;26: 545&#8211;566.</td><td><a href=http://dx.doi.org/10.1016/0010-7824(82)90131-7>10.1016/0010-7824(82)90131-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92</td><td>BibArticle</td><td>Landgren BM, Diczfalusy E. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.<Emphasis Type="Italic">Contraception</Emphasis>. 1984;29:437&#8211;446.</td><td><a href=http://dx.doi.org/10.1016/0010-7824(84)90017-9>10.1016/0010-7824(84)90017-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR93</td><td>BibArticle</td><td>Landgren BM, Csemiczky G. The effect of follicular growth and luteal function of &#8220;missing the pill&#8221;. A comparison between a monophasic and a triphasic combined oral contraceptive.<Emphasis Type="Italic">Contraception.</Emphasis> 1991;43:149&#8211;159.</td><td><a href=http://dx.doi.org/10.1016/0010-7824(91)90042-E>10.1016/0010-7824(91)90042-E</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR94</td><td>BibArticle</td><td>Cross JT, Lee HD, Nelson JS, et al. One in five marketed drugs undergoes a dosage change: 1980&#8211;1999.<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 2001;69:P63.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR95</td><td>BibArticle</td><td>Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.<Emphasis Type="Italic">JAMA</Emphasis>. 1998;279:1200&#8211;1205.</td><td><a href=http://dx.doi.org/10.1001/jama.279.15.1200>10.1001/jama.279.15.1200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96</td><td>BibArticle</td><td>Fremont-Smith K, Kravitz GR, Bush T, et al. Adverse drug reactions in hospitalized patients.<Emphasis Type="Italic">J Am Stat Assoc.</Emphasis> 1998;280:1741.</td><td><a href=http://dx.doi.org/10.1001/jama.280.20.1741>10.1001/jama.280.20.1741</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, ArticleTitle, Year, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR97</td><td>BibArticle</td><td>Burney KD, Krishnan K, Ruffin MT, et al. Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring.<Emphasis Type="Italic">Arch Farm Med.</Emphasis> 1996;5:297&#8211;300.</td><td><a href=http://dx.doi.org/10.1001/archfami.5.5.297>10.1001/archfami.5.5.297</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR98</td><td>BibArticle</td><td>Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications.<Emphasis Type="Italic">Ann Intern Med.</Emphasis> 2001;134:1004&#8211;1006.</td><td><a href=http://dx.doi.org/10.7326/0003-4819-134-10-200105150-00015>10.7326/0003-4819-134-10-200105150-00015</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR99</td><td>BibArticle</td><td>Meredith PA, Elliott HL. Therapeutic coverage: reducing the risks of partial compliance.<Emphasis Type="Italic">Br J Clin Pract.</Emphasis> 1994;73(suppl):13&#8211;17.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR100</td><td>BibArticle</td><td>Detry JM. Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient Compliance.<Emphasis Type="Italic">Clin Cardiol.</Emphasis> 1994;17(suppl 3):III12-III16.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR101</td><td>BibArticle</td><td>Urquhart J, De Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens.<Emphasis Type="Italic">Stat Med.</Emphasis> 1998;17:251&#8211;267; discussion 387&#8211;389.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0258(19980215)17:3&lt;251::AID-SIM762&gt;3.0.CO;2-A>10.1002/(SICI)1097-0258(19980215)17:3&lt;251::AID-SIM762&gt;3.0.CO;2-A</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>